Brief: Alphamab Oncology Announces Clinical Supply Collaboration With Pfizer On Kn026 In Combination With Ibrance(R) (Palbociclib)
27/03/2020 11:50
March 27 (Reuters) - Alphamab Oncology 9966.HK :
* ALPHAMAB ONCOLOGY ANNOUNCES CLINICAL SUPPLY COLLABORATION
WITH
PFIZER ON KN026 IN COMBINATION WITH IBRANCE(R) (PALBOCICLIB)
* ALPHAMAB ONCOLOGY - HAS ENTERED CLINICAL SUPPLY AGREEMENT
WITH
PFIZER TO ADVANCE CLINICAL STUDY TO INVESTIGATE KN026 IN
COMBINATION WITH IBRANCE
* ALPHAMAB ONCOLOGY - UNIT JIANGSU ALPHAMAB
BIOPHARMACEUTICALS
CO., LTD WILL OVERSEE AND RUN TRIAL, AND PFIZER WILL SUPPLY
PALBOCICLIB
Source text for Eikon: ID:nPn6hm6lJa
Further company coverage: 9966.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Alphamab Oncology
See all newsBrief: Alphamab Oncology Says Fei Wang Resigns As Chief Financial Officer
Brief: Alphamab Oncology Says First Patient Dosed In Phase III Clinical Study Of JSKN033 Monotherapy For Treatment Of Cervical Cancer
Brief: Alphamab Oncology Says Board Resolves To Repurchase Shares Up To HK$80 Million In Value
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab With HB1801 For Her2+ Advanced Breast Cancer
Brief: Alphamab Oncology Says NMPA Accepts NDA For Anbenitamab (KN026)